The estimated Net Worth of Ulf Wiinberg is at least $1.26 Million dollars as of 15 November 2023. Mr. Wiinberg owns over 25,000 units of Agenus Inc stock worth over $699,715 and over the last 9 years he sold AGEN stock worth over $0. In addition, he makes $559,917 as Independent Director at Agenus Inc.
Ulf has made over 5 trades of the Agenus Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he bought 25,000 units of AGEN stock worth $19,000 on 15 November 2023.
The largest trade he's ever made was buying 30,000 units of Agenus Inc stock on 6 September 2016 worth over $188,700. On average, Ulf trades about 2,546 units every 55 days since 2016. As of 15 November 2023 he still owns at least 124,063 units of Agenus Inc stock.
You can see the complete history of Mr. Wiinberg stock trades at the bottom of the page.
Ulf Wiinberg serves as Independent Director of the Company. Mr. Wiinberg has almost 20 years of senior leadership experience, most recently serving as Chief Executive Officer of H. Lundbeck A/S (“Lundbeck”) from June 2008 to December 2014. Lundbeck is a global pharmaceutical company developing and marketing treatments for psychiatric and neurological disorders. He previously served on the boards of several health care industry associations and held multiple executive roles at Wyeth, one of the world’s largest research-driven pharmaceutical companies that was acquired by Pfizer in 2009. He served as President of Wyeth Europe, Africa and Middle East; President of Consumer Healthcare; Managing Director of Wyeth UK, and in various commercial positions. Mr. Wiinberg currently serves on the boards of UCB SA, a global biopharmaceutical company based in Belgium, Avillion LLP (Chairman), a London-based drug development company, Hansa Medical AB (Chairman), a Swedish biopharmaceutical company, and Alfa Laval AB, a Swedish industrial company. Mr. Wiinberg brings to our Board years of experience in the biotechnology, pharmaceutical and healthcare industries internationally.
As the Independent Director of Agenus Inc, the total compensation of Ulf Wiinberg at Agenus Inc is $559,917. There are 7 executives at Agenus Inc getting paid more, with Garo Armen having the highest compensation of $9,937,040.
Ulf Wiinberg is 61, he's been the Independent Director of Agenus Inc since 2016. There are 6 older and 7 younger executives at Agenus Inc. The oldest executive at Agenus Inc is Wadih Jordan, 85, who is the Independent Director.
Ulf's mailing address filed with the SEC is C/O AGENUS INC., 3 FORBES ROAD, LEXINGTON, MA, 02421.
Over the last 23 years, insiders at Agenus Inc have traded over $24,466,328 worth of Agenus Inc stock and bought 13,248,226 units worth $63,837,873 . The most active insiders traders include Associates Gp Llcqvt Fund V..., Noubar Afeyan, and Corp Incyte. On average, Agenus Inc executives and independent directors trade stock every 99 days with the average trade being worth of $2,230,885. The most recent stock trade was executed by Garo H Armen on 15 February 2024, trading 500,000 units of AGEN stock currently worth $325,000.
agenus is an immunology company discovering and developing novel checkpoint modulators, vaccines and adjuvants to treat cancer and other diseases. we are a dedicated group of scientists, researchers, biotechnologists, physicians, and businesspeople working together toward one goal: to discover and develop therapies that can unleash the innate power of the body’s immune system to treat and potentially cure hard-to-treat cancers and other diseases. our product candidates are designed to work by educating and activating the body’s immune system for a precise and potent attack on cancer. our strategy is to help unlock the potential of one of the most exciting breakthrough areas in cancer treatment in decades, and to develop single agent and combination immune-oncology therapies that can help save lives. our approaches are driven by three platform technologies, including: • our antibody platforms, including our proprietary retrocyte display™ and secant® technologies, and our antibody
Agenus Inc executives and other stock owners filed with the SEC include: